Abstract
AbstractThe re-emergence of yellow fever (YF) urged new mass vaccination campaigns and, in 2017, the World Health Organization approved the use of the fractional dose (FD) of the YF vaccine due to stock shortage. In an observational cross-sectional investigation, we have assessed viremia, antibodies, soluble mediators and effector and memory T and B-cells induced by primary vaccination of volunteers with FD and standard dose (SD). Similar viremia and levels of antibodies and soluble markers were induced early after immunization. However, a faster decrease in the latter was observed after SD. The FD led to a sustained expansion of helper T-cells and an increased expression of activation markers on T-cells early after vaccination. Although with different kinetics, expansion of plasma cells was induced upon SD and FD immunization. Integrative analysis reveals that FD induces a more complex network involving follicular helper T cells and B-cells than SD. Our findings substantiate that FD can replace SD inducing robust correlates of protective immune response against YF.
Publisher
Springer Science and Business Media LLC
Reference67 articles.
1. World Health Organization. Yellow Fever Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/yellow-fever (2019).
2. Centers for Disease Control and Prevention. Yellow Fever Virus. https://www.cdc.gov/yellowfever/index.html (2019).
3. Vasconcelos, P. F. D. C. Febre amarela: reflexões sobre a doença, as perspectivas para o século XXI e o risco da reurbanização. Rev. Bras. Epidemiol. 5, 244–258 (2002).
4. Theiler, M. & Smith, H. H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65, 787–800 (1937).
5. Kimathi, D. et al. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial. Lancet Infect. Dis. 23, 974–982 (2023).